Biocon Ltd, along with its subsidiary Biocon Biologics, has been named among the Top 10 employers in the global biotech, pharma and biopharma sector by the peer-reviewed US-based journal Science. Employees of Biocon and Biocon Biologics participated in a Top Employers’ Survey conducted by Science. Biocon has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees.’
Press Release
Features in ‘Science 2022 Top Employer List’ of Best pharma, biotech & biopharma employers globally, for the 10th Consecutive Year
Bengaluru, Karnataka, India, October 31, 2022
Biocon Ltd, an innovation-led global biopharmaceuticals company, announced today it has been named among the Top 10 employers in the global biotech, pharma and biopharma sector by the prestigious U.S.-based Science magazine. Biocon has been ranked 8th on the list this year for three key attributes: ‘innovative leader in the industry’, ‘is socially responsible’ and ‘has loyal employees.’
Employees across Biocon and Biocon Biologics participated in the Top Employers Survey conducted by Science magazine. This marks the tenth consecutive time that Biocon has been included in the journal’s prestigious annual global ranking. The Company ranked ahead of pharma & biotech majors such as Vertex, Merck, Genentech, GSK, Abbott, Roche, Novartis, etc. this year.
For the companies that emerged in the Top 20, remarks from survey respondents reflected that scientists positioned passion as a top metric for their choice of employers. The survey also revealed that an investment in human resources development is often the one that produces the biggest return on investment.
Biocon Group prides itself on a meritocratic and value-driven culture, which is appreciated by its over 15,000-strong workforce.
Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics, said, “We are pleased to be recognized amongst the Top 20 Global Employers by the prestigious Science magazine for the 10th consecutive year. This year’s rank of No. 8 for Biocon Group reflects the passion of our people to make a lasting impact on global health. We have always focussed on creating a workplace culture that encourages ideation, collaboration and experimentation. This culture, which is fully aligned with the organization’s vision and values, enables our employees to achieve their full potential through innovative thinking and a sense of unwavering purpose. This global ranking is a recognition of the quality of our talent pool and their commitment towards serving patients through innovative science.”
Since 2002, Science has been studying the best organizations in biotech, pharma, and biopharma as part of its Top Employers Survey through which its readers choose 20 of the best worldwide companies. The survey shows that top employers pursue a systematic approach to professional development and advancement, as well as recognize that to attract the best scientific talent, they need to create a space for creativity, exploration and innovation.
To this end, Biocon regularly implements talent strategies to foster learning and growth for its employees thus ensuring a high-performance culture through education, exposure and experiences. It deploys a comprehensive training program to re-skill and cross-skill its employees. Moreover, there are several initiatives that enable employees to fulfil their individual career development aspiration, thereby, helping retain talent.
| Science 2022 Top Twenty Employers | |||||||
| 2022 Rank |
2021 Rank |
Employer (Global Headquarters) | Innovative leader in the industry | Treats employees with respect |
Is socially responsible | Provides employees with autonomy | Has loyal employees |
| 1 | 1 | Insmed (Bridgewater, NJ) | • | • | • | ||
| 2 | 3 | Alnylam Pharmaceuticals (Cambridge, MA) | • | • | • | ||
| 3 | 4 | Regeneron (Tarrytown, NY) | • | • | • | ||
| 4 | 2 | Incyte (Wilmington, DE)) | • | • | • | ||
| 5 | 6 | Syngenta Group (Basel, Switzerland) | • | • | • | ||
| 6 | 5 | Spark Therapeutics (Philadelphia, PA) | • | • | • | ||
| 7 | 7 | Moderna (Cambridge, MA) | • | • | • | ||
| 8 | 12 | Biocon Limited (Bangalore, India) | • | • | • | ||
| 9 | 8 | Vertex Pharmaceuticals (Boston, MA) | • | • | • | ||
| 10 | 9 | Merck KGaA (Darmstadt, Germany) | • | • | • | ||
| 11 | 10 | Genentech (South San Francisco, CA) | • | • | • | ||
| 12 | 17 | GSK (London, United Kingdom) | • | • | • | ||
| 13 | 11 | Abbott (Abbott Park, IL) | • | • | • | ||
| 14 | 20 | Roche – excluding Genentech (Basel, Switzerland) | • | • | • | ||
| 15 | 14 | Takeda Pharmaceutical Company Limited (Tokyo, Japan) | • | • | • | ||
| 16 | 15 | Novo Nordisk (Bagsvaerd, Denmark) | • | • | • | ||
| 17 | 19 | Novartis (Basel, Switzerland) | • | • | • | ||
| 18 | — | Dr. Reddy’s Laboratories Limited (Hyderabad, India) | • | • | • | ||
| 19 | 18 | Eli Lilly and Company (Indianapolis, IN) | • | • | • | ||
| 20 | — | Boehringer Ingelheim (Ingelheim, Germany) | • | • | • | ||
The 20 companies with the best reputation as employers and the top three driving characteristics for each company, according to respondents in the 2022 survey undertaken for the Science/AAAS Custom Publishing Office.
The companies without a 2021 rank did not receive enough mentions to qualify or did not receive a high enough ranking from the 2021 survey.
This year, the global survey was completed by over 6,200 respondents, who came from North America (63%), Europe (15%), Asia/Pacific Rim (17%), Rest of the World (5%). Also, 32% worked in biotechnology, 38% in biopharma, 22% in pharma and 8% in others.
The Top 20 companies were selected using a statistical process that calculates a unique ranking score for each company rated. Organizations that are seen as innovative leaders in the industry, that respect their employees, that have loyal employees who are provided the autonomy of decision making they need to do their best, and that are socially responsible are selected as best in class, according to Cell Associates, LLC, which conducted the survey.
About Biocon Limited
Biocon Limited, publicly listed in 2004, (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is an innovation-led global biopharmaceuticals company committed to enhance affordable access to complex therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US and Europe. It also has a pipeline of promising novel assets in immunotherapy under development. Website: www.biocon.com; Follow-us on Twitter: @bioconlimited for company updates.
About Biocon Biologics Ltd.
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., is a unique, fully integrated global biosimilars organization. It is leveraging cutting-edge science, innovative tech platforms and advanced research & development capabilities to lower costs of biologics therapies while improving healthcare outcomes. It has a strong research pipeline of biosimilar molecules across diabetes, oncology, immunology and other non-communicable diseases. Seven molecules from Biocon Biologics’ portfolio have been commercialized in key emerging markets and developed markets like U.S., EU, Australia, Canada, Japan. It has many firsts to its credit including the most recent U.S. FDA approval of the world’s first interchangeable biosimilar, awarded to its Insulin Glargine, which has been commercialized in the U.S. in 2021. Biocon Biologics has signed a strategic alliance with Serum Institute Life Sciences (subject to certain closing conditions) to address the inequitable access to lifesaving vaccines and biologics globally. With a team of over 5,000 people, Biocon Biologics is committed to transforming healthcare and transforming lives by enabling affordable access to millions of patients’ worldwide. Website: www.bioconbiologics.com; Follow us on Twitter: @BioconBiologics for company updates.
Download Press Release